UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer

Marriott, ER; Van Hazel, G; Gibbs, P; Hatswell, AJ; (2017) Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer. Journal of Medical Economics , 20 (2) pp. 193-199. 10.1080/13696998.2016.1241788. Green open access

[thumbnail of Hatswell_2016-09-09_EORTC to EQ-5D mapping_JME_revised_CLEAN complete.pdf]
Preview
Text
Hatswell_2016-09-09_EORTC to EQ-5D mapping_JME_revised_CLEAN complete.pdf - Accepted Version

Download (701kB) | Preview

Abstract

AIMS: The primary aim of this study was to perform a mapping of the EORTC-QLQ-C30 scores to EQ-5D-3L for the SIRFLOX study; a large dataset of patients with previously untreated liver-only or liver-dominant metastatic colorectal cancer (mCRC). A secondary aim was to compare the predictive validity of existing mappings from EORTC-QLQ-C30 to EQ-5D-3L conducted in other cancers. METHODS AND MATERIALS: Questionnaires (completed within 529 patients) were used in a linear mixed regression to model EQ-5D-3L utility values (scored using the UK tariff) as a function of the five function scores, nine symptom scores and the global score from the EORTC-QLQ-C30 questionnaire. A Tobit regression was also performed. The mean EQ-5D-3L values for the SIRFLOX trial were calculated and compared with predicted EQ-5D-3L values derived using published. RESULTS: The linear mixed regression model provided a satisfactory mapping between the EORTC-QLQ-C30 and the EQ-5D-3L, whilst the Tobit model did not perform as well. When utilities from the SIRFLOX data were calculated with previously published mapping studies, three out of five studies performed well (<10% mean difference). LIMITATIONS: The main limitation of the study was the lack of meaningful observations post-progression (67 paired observations). For this reason, we were unable to test whether the mapping holds by disease stage. Additionally, although the study adds to the literature of mappings to the EQ-5D-3L, it is not known how results would differ using the EQ-5D-5L. CONCLUSION: This study is the first of its kind in liver-only or liver-dominant mCRC, and mCRC in general. The mapping constructed showed a good fit to the data and provides practitioners with an additional mapping between EORTC-QLQ-C30 to EQ-5D-3L using a large dataset (529 patients, 707 paired observations). The study also confirmed the generalisability of mappings published by Proskorovsky, Kontodimopoulos and Longworth to liver-only or liver-dominant mCRC.

Type: Article
Title: Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer
Open access status: An open access version is available from UCL Discovery
DOI: 10.1080/13696998.2016.1241788
Publisher version: http://doi.org/10.1080/13696998.2016.1241788
Language: English
Additional information: This is an Accepted Manuscript of an article published by Taylor & Francis in the Journal of Medical Economics on 13 October 2016, available online: http://www.tandfonline.com/10.1080/13696998.2016.1241788.
Keywords: Health-related quality of life, cost-utility, health state utility, patient-reported outcomes, quality of life
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences > Dept of Statistical Science
URI: https://discovery-pp.ucl.ac.uk/id/eprint/1520663
Downloads since deposit
15,650Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item